Eli Lilly developed tirzepatide, marketed as Mounjaro and Zepbound.
Eli Lilly and Company was founded in Indianapolis in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Union veteran. The company initially emphasized reliable manufacturing and quality standards at a time when medicine quality could vary substantially.
Tirzepatide is a once-weekly injectable medicine that activates receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Eli Lilly markets it as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management in eligible patients.
A common mix-up is confusing tirzepatide with semaglutide, a different medicine developed by Novo Nordisk and sold under brands including Ozempic and Wegovy. Mounjaro and Zepbound therefore share a therapeutic area with those products but do not contain the same active ingredient.